News summary

Alzheimer’s blood test lines up Japan approval bid

Source: Longevity Technology • Published: 19 Nov 2026, 15:56

Summarized by Masters of Longevity from Longevity Technology.

A Tokyo lab is pursuing approval for PrecivityAD2 after US accuracy results.

Alzheimer’s blood test lines up Japan approval bid
Key Takeaways
  • About 97.6% of positive PrecivityAD2 tests had brain amyloid.
  • About 93.1% of negative PrecivityAD2 tests lacked brain amyloid.
  • Study accuracy is based on diagnostic validation, not causal proof.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.